News

Two Additional Organic Compliance Listings Obtained for AgroSpheres Novel Encapsulation Platform for Use in Organic Crop Production

AgroSpheres, Inc., an agricultural biobased solutions developer, recently received certificates attesting to the organic input compliance of its proprietary encapsulation technology, AgroSpheres® Microbially-Derived Minicells (also known as the AgriCell), and its formulated encapsulated thyme oil product, Thyme Oil 26% LC Biofungicide from the Organic Materials Review Institute (OMRI). OMRI, the leading certifier of organic inputs for agriculture, has determined that both products meet the criteria for use under the USDA National Organic Program (NOP).

AgroSpheres® Microbially-Derived Minicells is now listed in OMRI’s Generic Material Listing for use as (1) an inert ingredient in organic crop pest, weed, and disease control and (2) as an adjuvant for use in fertilizers and soil amendments in crop management tools and production aids.

Thyme Oil 26% LC Biofungicide is now listed by OMRI as a biopesticide for use in crop pest, weed, and disease control.

AgroSpheres® Microbially-Derived Minicells may be used as an adjuvant in fertilizers and soil amendments beginning immediately.

However, for crop pest, weed, and disease control uses, please note that both AgroSpheres® Microbially-Derived Minicells and Thyme Oil 26% LC Biofungicide are currently pending review and approval by US EPA. Once those approvals are granted, they will be available for use in organic and conventional crop production.

These certificates symbolize that these AgroSpheres’ products meet the stringent criteria NOP has created for the organic industry. This significant milestone marks a major step forward in advancing environmentally friendly and efficient agricultural practices.

“We are extremely pleased to have received this acknowledgement from OMRI. This certification opens up our ability to sell to all growers and provide tools for organic growers that are in desperate need. In our previous year of field trials, our Thyme Oil 26% product performed very well against both OMRI and conventional products,” said Reese Blackwell, Chief Business Officer for AgroSpheres.

In recent field trials, growers have not only seen great product efficacy but also added plant health benefits of this OMRI product. Below are a couple of the grower remarks that AgroSpheres received in last season’s trial program.

  • “You could notice a difference in the crop between treatments. When we dropped the crop to the ground in the AgroSpheres treatment area, the overall crop quality looked better vs. the other treatments in the field.” – Grape Grower (Sacramento, CA)
  • “Overall plant health looks better in the AgroSpheres treatment vs. the untreated control, and the competitive product.” – Almond Grower (Crows Landing, CA)

The encapsulated products will be sold through various distributors after product approvals.

To see a complete list of the OMRI Listed® certificates for AgroSpheres® products, click here.

Recent News

05/22/2026

BIO Statement on Veto of Prescription Drug Affordability Boards (PDAB) in VirginiaPatrick J. Plues, Senior Vice President of State Government Affairs & Affiliate Relations at the Biotechnology Innovation Organization (BIO) released the following statement on the veto of Prescription Drug Affordability Boards (PDAB) legislation in Virginia: “BIO applauds Governor Spanberger’s decision to veto SB 271 and HB 483 — legislation that would have established a Prescription Drug Affordability Board (PDAB) and imposed arbitrary price controls in Virginia. The Governor’s action recognized an important point: even well-intentioned healthcare policies must be carefully designed to avoid unintended consequences for patients, providers, employers, and Virginia’s innovation economy. “BIO is proud to represent biotechnology companies developing the next generation of life-changing medicines, including many in the Commonwealth. We believe policymakers play a critically important role in helping advance both patient access to treatments and the continued growth of the life sciences sector. “We look forward to working with the Governor’s Administration, the General Assembly, Virginia Bio and other stakeholders to advance practical, patient-centered policy solutions that improve affordability while preserving access to care and the innovation ecosystem patients depend on.”

Patrick J. Plues, Senior Vice President of State Government Affairs & Affiliate Relations at the Biotechnology Innovation Organization (BIO) released the following statement on the veto of Prescription Drug Affordability Boards (PDAB) legislation in Virginia: “BIO applauds Governor Spanberger’s decision to veto SB 271 and HB 483 — legislation that would have established a Prescription

05/21/2026

Virginia Bio Applauds Governor Spanberger’s Veto of SB 271 and HB 483

The Virginia Biotechnology Association (Virginia Bio) today expressed strong support for Governor Abigail Spanberger’s decision to veto Senate Bill 271 and House Bill 483, legislation that would have established a Prescription Drug Affordability Advisory Panel (PDAAP) in the Commonwealth. Virginia Bio and the Virginia Chamber of Commerce sent a joint letter to Governor Spanberger commending

05/21/2026

New Global Clinical Society to Bring Focused Ultrasound Into Mainstream Medicine

The Focused Ultrasound Foundation today announced the launch of the International Focused Ultrasound Society (IFUS), a new organization dedicated to advancing clinical practice and accelerating adoption of focused ultrasound – a revolutionary, noninvasive therapeutic technology. Established as a program of the Focused Ultrasound Foundation, IFUS aggregates and expands the Foundation’s activities related to clinical implementation